PMID- 18469338
OWN - NLM
STAT- MEDLINE
DCOM- 20081003
LR  - 20211020
IS  - 0008-6363 (Print)
IS  - 1755-3245 (Electronic)
IS  - 0008-6363 (Linking)
VI  - 79
IP  - 4
DP  - 2008 Sep 1
TI  - Cross-talk between cytokines and renin-angiotensin in hypothalamic 
      paraventricular nucleus in heart failure: role of nuclear factor-kappaB.
PG  - 671-8
LID - 10.1093/cvr/cvn119 [doi]
AB  - AIMS: Nuclear factor-kappa B (NF-kappaB) is a potent inducer of pro-inflammatory 
      cytokines (PIC) and oxidative stress in cardiovascular disease. In this study, we 
      determined whether upregulation of NF-kappaB in the hypothalamic paraventricular 
      nucleus (PVN) contributed to neurohumoral excitation either directly, or via 
      interaction with the renin-angiotensin system (RAS), in heart failure (HF). 
      METHODS AND RESULTS: Rats were implanted with intracerebroventricular (ICV) 
      cannulae and subjected to coronary artery ligation, or sham surgery (SHAM). 
      Subsequently, animals were ICV treated with the angiotensin type 1 receptor 
      (AT1-R) antagonist losartan (LOS, 20 microg/h), or SN50 (2 microg/h), which 
      inhibits nuclear translocation of NF-kappaB, or tempol (TEMP, 80 microg/h), a 
      membrane-permeable superoxide scavenger, or vehicle for 4 weeks. HF induced a 
      significant increase in the expression of AT1-R, PIC, and NAD(P)H oxidase genes 
      and NF-kappaB p50 in the PVN and in plasma norepinephrine (NE) levels when 
      compared with SHAM rats. In contrast, ICV LOS, SN50, or TEMP attenuated PIC, 
      NF-kappaB p50, AT1-R and NAD(P)H oxidase genes in the PVN compared with 
      vehicle-treated HF rats. Treatment with LOS, SN50, or TEMP also reduced plasma 
      levels of NE, angiotensin II, and PIC, and decreased left ventricular end 
      diastolic pressure. CONCLUSION: These findings indicate that NF-kappaB mediates 
      the cross-talk between RAS and PIC in the PVN in HF, and that superoxide 
      stimulates more NF-kappaB in the PVN and contributes to neurohumoral excitation.
FAU - Kang, Yu-Ming
AU  - Kang YM
AD  - Shanxi Medical University, Taiyuan 030001, People's Republic of China. 
      ymkang@lsu.edu
FAU - Ma, Ying
AU  - Ma Y
FAU - Elks, Carrie
AU  - Elks C
FAU - Zheng, Jin-Ping
AU  - Zheng JP
FAU - Yang, Zhi-Ming
AU  - Yang ZM
FAU - Francis, Joseph
AU  - Francis J
LA  - eng
GR  - R01 HL080544/HL/NHLBI NIH HHS/United States
GR  - R01-HL-080544-01/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20080510
PL  - England
TA  - Cardiovasc Res
JT  - Cardiovascular research
JID - 0077427
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Cyclic N-Oxides)
RN  - 0 (Cytokines)
RN  - 0 (Free Radical Scavengers)
RN  - 0 (NF-kappa B p50 Subunit)
RN  - 0 (Peptides)
RN  - 0 (Receptor, Angiotensin, Type 1)
RN  - 0 (SN50 peptide)
RN  - 0 (Spin Labels)
RN  - 11062-77-4 (Superoxides)
RN  - EC 1.6.3.- (NADPH Oxidases)
RN  - JMS50MPO89 (Losartan)
RN  - U78ZX2F65X (tempol)
SB  - IM
MH  - Angiotensin II Type 1 Receptor Blockers/administration & dosage
MH  - Animals
MH  - Cyclic N-Oxides/administration & dosage
MH  - Cytokines/blood/*metabolism
MH  - Disease Models, Animal
MH  - Free Radical Scavengers/administration & dosage
MH  - Heart Failure/diagnostic imaging/drug therapy/*metabolism/physiopathology
MH  - Hemodynamics
MH  - Infusions, Parenteral
MH  - Losartan/administration & dosage
MH  - Male
MH  - NADPH Oxidases/metabolism
MH  - NF-kappa B p50 Subunit/antagonists & inhibitors/genetics/*metabolism
MH  - Paraventricular Hypothalamic Nucleus/drug effects/*metabolism
MH  - Peptides/administration & dosage
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptor, Angiotensin, Type 1/metabolism
MH  - *Renin-Angiotensin System/drug effects/genetics
MH  - *Signal Transduction/drug effects
MH  - Spin Labels
MH  - Superoxides/metabolism
MH  - Ultrasonography
MH  - Ventricular Function, Left
PMC - PMC2732061
EDAT- 2008/05/13 09:00
MHDA- 2008/10/04 09:00
PMCR- 2009/09/01
CRDT- 2008/05/13 09:00
PHST- 2008/05/13 09:00 [pubmed]
PHST- 2008/10/04 09:00 [medline]
PHST- 2008/05/13 09:00 [entrez]
PHST- 2009/09/01 00:00 [pmc-release]
AID - cvn119 [pii]
AID - 10.1093/cvr/cvn119 [doi]
PST - ppublish
SO  - Cardiovasc Res. 2008 Sep 1;79(4):671-8. doi: 10.1093/cvr/cvn119. Epub 2008 May 
      10.